Edwards Lifesciences Corporation Company Profile (NYSE:EW)

Edwards Lifesciences Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences Corporation's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences Corporation stock prior to the split would have 200 shares after the split.

Edwards Lifesciences Corporation (NYSE:EW) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $1.08 EPS for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.20. The company earned $842 million during the quarter, compared to analysts' expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation's revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.76 EPS. View Edwards Lifesciences Corporation's Earnings History.

Edwards Lifesciences Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $3.65-3.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.54. The company issued revenue guidance of $, compared to the consensus revenue estimate of $3.35 billion.Edwards Lifesciences Corporation also updated its Q3 guidance to $0.80-0.90 EPS.

20 analysts have issued 12 month target prices for Edwards Lifesciences Corporation's stock. Their forecasts range from $14.00 to $155.00. On average, they expect Edwards Lifesciences Corporation's stock price to reach $120.05 in the next twelve months. View Analyst Ratings for Edwards Lifesciences Corporation.

Here are some recent quotes from research analysts about Edwards Lifesciences Corporation stock:

• 1. According to Zacks Investment Research, "Over the last six months, Edwards Lifesciences has outperformed the broader industry. Edwards Lifesciences’ second-quarter 2017 performance was quite promising . Moreover, the raised guidance for 2017 hints at brighter prospects. In fact, the guidance raise was backed by a strong performance by all of the company’s three product lines.   We believe that the recent FDA approvals for several products including SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting investors’ confidence on the stock. However, higher operating expenses raise concerns. The stock’s valuation is also stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (9/26/2017)
• 2. Cowen and Company analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
• 3. Evercore ISI analysts commented, "With lowered investor expectations, we believe EW shares are poised for a 'catch-up' trade and offers asymmetric risk-reward at current levels. As a result, we are upgrading shares to a Buy, and raising our PT to $110, which offers ~15% upside from current levels." (3/27/2017)

Edwards Lifesciences Corporation saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 3,127,319 shares, an increase of 49.6% from the August 31st total of 2,090,850 shares. Based on an average daily trading volume, of 1,430,982 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.5% of the company's shares are short sold.

Some companies that are related to Edwards Lifesciences Corporation include Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY) and Accelerate Diagnostics (AXDX).

Edwards Lifesciences Corporation's management team includes the folowing people:

• Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
• Scott B. Ullem, Chief Financial Officer, Corporate Vice President
• Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
• Catherine M. Szyman, Corporate Vice President- Critical Care
• Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
• Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
• Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
• Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
• Kieran T. Gallahue, Independent Director
• Leslie Stone Heisz, Independent Director

Edwards Lifesciences Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include Fulton Bank N.A. (0.01%) and Bath Savings Trust Co (0.01%). Company insiders that own Edwards Lifesciences Corporation stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. Company insiders that have sold Edwards Lifesciences Corporation stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Huimin Wang, Larry L Wood, Michael A Mussallem and Patrick B Verguet. View Insider Buying and Selling for Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Bath Savings Trust Co. Company insiders that have bought Edwards Lifesciences Corporation stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences Corporation.

Shares of Edwards Lifesciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Edwards Lifesciences Corporation stock can currently be purchased for approximately $112.03.